Results overview: Found 1 records in 0.03 seconds.
Articles, 1 records found
Articles 1 records found  
1.
10 p, 4.0 MB Eculizumab discontinuation in atypical haemolytic uraemic syndrome : TMA recurrence risk and renal outcomes / Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Fakhouri, Fadi (CHU de Nantes) ; Sartz, Lisa (Skåne University Hospital (Suècia)) ; Miller, Benjamin (Alexion Pharmaceutical (Estats Units d'Amèrica)) ; Nikolaou, Vasilis (Parexel International (Regne Unit)) ; Cohen, David (Columbia University Medical Center) ; Siedlecki, Andrew M. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ; Ardissino, Gianluigi (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico) ; Universitat Autònoma de Barcelona
Eculizumab modifies the course of disease in patients with atypical haemolytic uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe are limited. Patients enrolled in the Global aHUS Registry who received ≥1 month of eculizumab before discontinuing, demonstrated haematologic or renal response prior to discontinuation and had ≥6 months of follow-up were analysed. [...]
2021 - 10.1093/ckj/sfab005
Clinical Kidney Journal, Vol. 14 (january 2021) , p. 2075-2084  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.